Trending...
- Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
- Peter J. D'Arruda Founder of Capital Financial Joins Tom Hegna on the Podcast "Financial Freedom with Tom Hegna"
DURHAM, N.C.--(BUSINESS WIRE)--Target RWE, a leading real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries based in Durham, North Carolina, today announced the acquisition of NoviSci, Inc., a software analytics and services company whose innovative technologies enable the visualization and analysis of health data using modern epidemiological methods and sound scientific principles. The acquisition significantly broadens Target RWE's data analytics capabilities and will enable the company to meet increasing demand for high quality evidence from real-world data.
Related to this acquisition, Amgen Inc., a strategic investor in and collaborator with NoviSci, has also made a strategic investment in the combined company to fuel growth, joining existing Target RWE investors Norwest Venture Partners and 22C Capital. This expanded partnership further validates the importance of real-world data on a global scale and the differentiated capabilities and solutions that Target RWE and NoviSci offer together. Financial terms of the transactions were not disclosed.
Neal Bibeau, Chief Executive Officer of Target RWE, said, "Target RWE's proven real-world data and evidence solutions continue to grow in breadth, depth and value for our research and industry partners. With the addition of NoviSci's novel analytics platform and experienced team, Target provides a highly adaptive environment to accelerate insights and reproducible research output from real-world data to various stakeholders in the healthcare ecosystem, including our pharmaceutical industry partners, healthcare investigator partners, government agencies and payor organizations."
More on ncarol.com
"Now more than ever, real-world evidence solutions are transforming healthcare. Our expanding longitudinal, observational data augmented with new sources of data allow for deep characterization of patient journeys across a broad range of diseases and treatments," added Michael W. Fried, MD, FAASLD, Chief Medical Officer and Co-founder of Target RWE. "NoviSci's expertise and novel analytical software complements our leading real-world evidence platform, and we look forward to integrating these products to enable accelerated growth in our industry."
Durham-based NoviSci, Inc. applies epidemiologic methods and causal inference techniques from the fields of epidemiology and statistics to complex real-world data to support its partners in research and industry. NoviSci has built a novel repository of rigorously developed interactive real-world studies that can be adapted to new datasets and populations. All study results are rendered in NoviSci's secure web-based environment, featuring interactive content and compelling data visualizations that can be updated with accumulating data. NoviSci's tools also support all critical aspects of scientific knowledge production, peer review, and sharing.
M. Alan Brookhart Ph.D., Co-Founder and Chief Scientist of NoviSci and Professor of Population Health Sciences at Duke University, said, "We are delighted to have the opportunity to apply our analytic technology to Target RWE's unique data assets and to provide timely, relevant, and useful answers to important questions posed by stakeholders across the healthcare ecosystem."
Aaron McKethan, Co-Founder and CEO of NoviSci added, "Our goal is to make it easier and faster to answer important questions in health care that result in better outcomes for people and populations. We have sought to use technology to bring the craft of scientific expertise to greater scale, particularly as research methods and data sources have become more complex."
More on ncarol.com
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE designs custom data sets, analyses, and evidence to address the complexities of healthcare evidence questions and quality initiatives. Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe, and other non-U.S. locations. Target RWE's data sets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Target RWE is backed by Norwest Venture Partners, 22C Capital and other strategic investors.
Visit www.targetrwe.com for more details.
About NoviSci Inc.
Headquartered in Durham, NC, NoviSci's mission is to use principled data science to improve population health outcomes for vulnerable patients with complex conditions. The company's novel analytic applications facilitate the efficient deployment of complex research methods from epidemiology and statistics as well as intuitive, interactive visualization of complex results from real-world studies. NoviSci's founders and leaders continue to hold faculty appointments, including at the Duke University School of Medicine and the University of North Carolina at Chapel Hill. NoviSci previously received seed investment from Amgen Ventures and Hatteras Venture Partners and is based in the American Underground campus in downtown Durham, NC.
Visit www.novisci.com for more details.
Related to this acquisition, Amgen Inc., a strategic investor in and collaborator with NoviSci, has also made a strategic investment in the combined company to fuel growth, joining existing Target RWE investors Norwest Venture Partners and 22C Capital. This expanded partnership further validates the importance of real-world data on a global scale and the differentiated capabilities and solutions that Target RWE and NoviSci offer together. Financial terms of the transactions were not disclosed.
Neal Bibeau, Chief Executive Officer of Target RWE, said, "Target RWE's proven real-world data and evidence solutions continue to grow in breadth, depth and value for our research and industry partners. With the addition of NoviSci's novel analytics platform and experienced team, Target provides a highly adaptive environment to accelerate insights and reproducible research output from real-world data to various stakeholders in the healthcare ecosystem, including our pharmaceutical industry partners, healthcare investigator partners, government agencies and payor organizations."
More on ncarol.com
- Costa Oil - 10 Minute Oil Change Surpasses 70 Locations with Construction of San Antonio, TX Stores — Eyes Growth Via Acquisition or Being Acquired
- LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
- Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- Children Rising Appoints Marshelle A. Wilburn as New Executive Director
"Now more than ever, real-world evidence solutions are transforming healthcare. Our expanding longitudinal, observational data augmented with new sources of data allow for deep characterization of patient journeys across a broad range of diseases and treatments," added Michael W. Fried, MD, FAASLD, Chief Medical Officer and Co-founder of Target RWE. "NoviSci's expertise and novel analytical software complements our leading real-world evidence platform, and we look forward to integrating these products to enable accelerated growth in our industry."
Durham-based NoviSci, Inc. applies epidemiologic methods and causal inference techniques from the fields of epidemiology and statistics to complex real-world data to support its partners in research and industry. NoviSci has built a novel repository of rigorously developed interactive real-world studies that can be adapted to new datasets and populations. All study results are rendered in NoviSci's secure web-based environment, featuring interactive content and compelling data visualizations that can be updated with accumulating data. NoviSci's tools also support all critical aspects of scientific knowledge production, peer review, and sharing.
M. Alan Brookhart Ph.D., Co-Founder and Chief Scientist of NoviSci and Professor of Population Health Sciences at Duke University, said, "We are delighted to have the opportunity to apply our analytic technology to Target RWE's unique data assets and to provide timely, relevant, and useful answers to important questions posed by stakeholders across the healthcare ecosystem."
Aaron McKethan, Co-Founder and CEO of NoviSci added, "Our goal is to make it easier and faster to answer important questions in health care that result in better outcomes for people and populations. We have sought to use technology to bring the craft of scientific expertise to greater scale, particularly as research methods and data sources have become more complex."
More on ncarol.com
- Fairmint CEO Joris Delanoue Elected General Director of the Canton Foundation
- Sleep Basil Mattress Co.'s Debuts New Home Page Showcasing Performance Sleep Solutions for Active Denver Lifestyles
- Bent Danholm Joins The American Dream TV as Central Florida Host
- Ability 2 Play Hosts Free Demo Day for Families in Raleigh/Garner Area
- The Nature of Miracles Celebrates 20th Anniversary Third Edition Published by DreamMakers Enterprises LLC
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE designs custom data sets, analyses, and evidence to address the complexities of healthcare evidence questions and quality initiatives. Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe, and other non-U.S. locations. Target RWE's data sets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Target RWE is backed by Norwest Venture Partners, 22C Capital and other strategic investors.
Visit www.targetrwe.com for more details.
About NoviSci Inc.
Headquartered in Durham, NC, NoviSci's mission is to use principled data science to improve population health outcomes for vulnerable patients with complex conditions. The company's novel analytic applications facilitate the efficient deployment of complex research methods from epidemiology and statistics as well as intuitive, interactive visualization of complex results from real-world studies. NoviSci's founders and leaders continue to hold faculty appointments, including at the Duke University School of Medicine and the University of North Carolina at Chapel Hill. NoviSci previously received seed investment from Amgen Ventures and Hatteras Venture Partners and is based in the American Underground campus in downtown Durham, NC.
Visit www.novisci.com for more details.
Filed Under: Business
0 Comments
Latest on ncarol.com
- IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention
- Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
- EnergyStrat Launches Global LNG Risk Outlook 2025–2030
- LTL Claims Ratio Index – Update 3Q25
- Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
- Billion Strong Foundation Upgrades 3X Skills + Career Finder and New AI Impact Engine
- Holiday Decorations Most Likely to Cause Injuries
- UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System
- CCHR Florida Joins Global Call to Ban Electroshock Treatment, Citing New Evidence of Widespread Patient Harm
- BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary
- UK Financial Ltd Announces It's Official Corporate Headquarters In The United Kingdom
- Greensboro's Leading Custom Sign Company Expands Services to Help Local Businesses Strengthen Their Brand Presence
- Rigani Press Announces Breakthrough Book for Health IT and Medical Leaders to Forge the Road to Responsible AI
- FreeTo.Chat - The bold, Anonymous Confession Platform, ushers in a new era of tension relief
- Cherokee Historical Association Hires Two New Staff Members to Lead New Programming Initiatives
- Hyatt House Fresno Celebrates Grand Opening, Introducing the First Hyatt House in Fresno, California
- "I Make Music Not Excuses" Journal by Anthony Clint Jr. Becomes International Amazon Best Seller, Empowering Music Creators Worldwide
- DanReDev, Kaufman Development & Oldivai Announce Major 2026 Projects Nationwide
- Trusted 24 Hour Mobile Locksmith In Raleigh NC
- More People Than Ever Want a Political Therapist: The Liberatory Wellness Network Is Building a New Standard of Care